China FDA Approves BGI NGS Assays Based on Ion Torrent and Complete Genomics NGS Technology | GenomeWeb

This story was originally published on July 8.

NEW YORK (GenomeWeb) – Earlier this month, the China Food and Drug Administration said it approved two next-generation sequencing-based diagnostic products developed by BGI — the first NGS assays to receive CFDA approval.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Browse our free articles
You can still register for access to our free content.

In PLOS this week: parent-of-origin effects, framework to uncover clinically important mutations from whole genome sequence data, and more.

A survey of Cincinnati schoolchildren finds teenagers want to know their genetic predisposition to disease, LiveScience reports.

More and more universities are helping their researchers patent their inventions, the Los Angeles Times reports.

Cancer Research UK unveils seven 'grand challenges' that it will fund researchers to tackle.

Sponsored by

This webinar will discuss the benefits of a rapid targeted next-generation sequencing (TNGS) panel, using dried blood spots, for second-tier newborn metabolic and hearing loss screening and its immediate utility for high-risk diagnostic testing in the neonatal intensive care unit. 

Sponsored by
Oracle Health Sciences

Brian Wells of Penn Medicine will detail how his team's "PennOmics" integrated healthcare data warehouse accelerates clinical trial recruitment at the point of care, accepts data from wearables, and does it all in a secure, HIPAA- and research-compliant fashion.